Skip to main content

Table 1 Clinical trials with immune checkpoint inhibitors and given adverse event profiles

From: Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer

Drug Author Tumor Type Number of Patients Taken off therapy secondary to toxicity Death secondary to therapy Elevation AST any grade Elevation AST grade 3–4 Elevation ALT any grade Elevation ALT grade 3–4 Diarrhea any grade Diarrhea grade 3–4
Tremelimumab Sangro et al. 2013 [14] HCC 20 3 0 14 9 11 5 6 1
Tremelimumab + ablation Duffy et al. 2016 [13] HCC 32 4 0 11 7 6 3 2 0
Nivolumab El-Khoueiry et al. 2017 [15] HCC 262 9 0 26 14 24 8 32 3
Pembrolizumab Garon et al. 2015 [33] NSCLC 495 NR NR 15 3 11 2 40 3
Pembrolizumab Reck et al. 2016 [34] NSCLC 154 11 1 NR NR NR NR 22 6
Pembrolizumab Herbst et al. 2016 [35] NSCLC 682 32 6 17 2 24 3 52 6
Nivolumab Borghaei et al. 2015 [36] NSCLC 287 14 1 9 1 9 0 22 2
Nivolumab Brahmer et al. 2015 [37] NSCLC 131 4 0 2 0 2 0 10 0
Nivolumab Rizvi et al. 2015 [38] NSCLC 117 14 2 0 0 1 0 12 3
Ipilimumab Wolchok et al. 2010 [39] Melanoma 214 35 0 NR NR NR NR 66 14
Ipilimumab Hodi et al. 2010 [23] Melanoma 131 17 4 1 0 2 0 46 13
Ipilimumab Robert et al. 2015 [40] Melanoma 256 24 1 6 2 9 2 79 26
Ipilimumab Eggermont et al. 2015 [22] Melanoma 471 245 5 78 20 102 25 270 81
Ipilimumab Larkin et al. 2015 [41] Melanoma 311 46 1 12 5 11 2 139 46
Tremelimumab Camacho et al. 2009 [42] Melanoma 89 10 0 NR NR NR NR 34 13
Tremelimumab Ribas et al. 2013 [43] Melanoma 325 43 7 NR NR NR NR 166 60
Tremelimumab Kirkwood et al. 2010 [44] Melanoma 246 13 2 NR NR NR NR 99 28
Pembrolizumab Robert et al. 2014 [45] Melanoma 173 6 0 5 0 6 0 22 1
Pembrolizumab Robert et al. 2015 [40] Melanoma 555 30 0 20 1 16 1 102 21
Pembrolizumab Ribas et al. 2015 [46] Melanoma 357 17 0 NR NR NR NR 34 2
Nivolumab Topalian et al. 2014 [47] Melanoma 107 17 0 4 0 5 0 19 2
Nivolumab Robert et al. 2015 [48] Melanoma 210 14 0 2 1 3 2 33 2
Nivolumab Weber et al. 2015 [49] Melanoma 268 7 0 11 1 7 2 30 1
Nivolumab Larkin et al. 2015 [41] Melanoma 313 24 1 12 3 12 4 64 9
Nivolumab Weber et al. 2016 [50] Melanoma 92 0 0 5 0 6 0 39 1
  1. HCC Hepatocellular Carcinoma, NSCLC Non-small cell lung cancer, AST aspartate aminotransferase, ALT alanine aminotransferase, NR not reported